CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca a Cancer J Clinicians. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. doi:10.1038/s41571-018-0073-4
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi:10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(4):203–222. doi:10.1038/s41575-022-00704-9
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Ozer M, Goksu SY, Akagunduz B, George A, Sahin I. Adoptive Cell Therapy in Hepatocellular Carcinoma: a Review of Clinical Trials. Cancers. 2023;15(6):1808.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international Phase 3 study. Lancet. 2023. doi:10.1016/S0140-6736(23)00961-3
   Web of Science ®Google Scholar
• Barrangou R, Fremaux C, Deveau H, et al. CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes. Science. 2007;315(5819):1709–1712. doi:10.1126/science.1138140
   PubMed Web of Science ®Google Scholar
• Liu G, Lin Q, Jin S, Gao C. The CRISPR-Cas toolbox and gene editing technologies. Molecular Cell. 2022;82(2):333–347. doi:10.1016/j.molcel.2021.12.002
   PubMed Web of Science ®Google Scholar
• Geurts MH, Clevers H. CRISPR engineering in organoids for gene repair and disease modelling. Nature Reviews Bioengineering. 2023;1(1):32–45. doi:10.1038/s44222-022-00013-5
   Google Scholar
• Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nat Biomed Eng. 2021;5(7):643–656. doi:10.1038/s41551-021-00760-7
   PubMed Web of Science ®Google Scholar
• Fellmann C, Gowen BG, Lin P-C, Doudna JA, Corn JE. Cornerstones of CRISPR–Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017;16(2):89–100. doi:10.1038/nrd.2016.238
   PubMed Web of Science ®Google Scholar
• Kan MJ, Doudna JA. Treatment of Genetic Diseases With CRISPR Genome Editing. JAMA. 2022;328(10):980–981. doi:10.1001/jama.2022.13468
   PubMed Web of Science ®Google Scholar
• Chavez M, Chen X, Finn PB, Qi LS. Advances in CRISPR therapeutics. Nat Rev Nephrol. 2023;19(1):9–22. doi:10.1038/s41581-022-00636-2
   PubMed Web of Science ®Google Scholar
• Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022;22(5):259–279. doi:10.1038/s41568-022-00441-w
   PubMed Web of Science ®Google Scholar
• Awwad SW, Serrano-Benitez A, Thomas JC, Gupta V, Jackson SP. Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens. Nat Rev Mol Cell Biol. 2023;24(7):477–494. doi:10.1038/s41580-022-00571-x
   PubMed Web of Science ®Google Scholar
• Palaz F, Kalkan AK, Can Ö, et al. CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research. ACS Synth. Biol. 2021;10(6):1245–1267. doi:10.1021/acssynbio.1c00107
   PubMed Web of Science ®Google Scholar
• Chiesa R, Georgiadis C, Syed F, et al. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2023;389(10):899–910. doi:10.1056/NEJMoa2300709
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. doi:10.1126/science.aba7365
   PubMed Web of Science ®Google Scholar
• Ottaviano G, Georgiadis C, Gkazi SA, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci, trans med. 2022;14(668):eabq3010. doi:10.1126/scitranslmed.abq3010
   PubMed Web of Science ®Google Scholar
• Lu Y, Xue J, Deng T, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nature Med. 2020;26(5):732–740. doi:10.1038/s41591-020-0840-5
   PubMed Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012;337(6096):816–821. doi:10.1126/science.1225829
   PubMed Web of Science ®Google Scholar
• Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci. 2012;109(39):E2579–E2586. doi:10.1073/pnas.1208507109
   PubMed Web of Science ®Google Scholar
• Cong L, Ran FA, Cox D, et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science. 2013;339(6121):819–823. doi:10.1126/science.1231143
   PubMed Web of Science ®Google Scholar
• Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nature Biotechnol. 2020;38(7):824–844. doi:10.1038/s41587-020-0561-9
   PubMed Web of Science ®Google Scholar
• Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell. 2022;185(15):2806–2827. doi:10.1016/j.cell.2022.03.045
   PubMed Web of Science ®Google Scholar
• Pickar-Oliver A, Gersbach CA. The next generation of CRISPR–Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490–507. doi:10.1038/s41580-019-0131-5
   PubMed Web of Science ®Google Scholar
• Nuñez JK, Chen J, Pommier GC, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184(9):2503–2519.e17. doi:10.1016/j.cell.2021.03.025
   PubMed Web of Science ®Google Scholar
• Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov. 2020;19(12):839–859. doi:10.1038/s41573-020-0084-6
   PubMed Web of Science ®Google Scholar
• Kuscu C, Parlak M, Tufan T, et al. CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations. Nature Methods. 2017;14(7):710–712. doi:10.1038/nmeth.4327
   PubMed Web of Science ®Google Scholar
• Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nature Biotechnol. 2018;36(8):765–771. doi:10.1038/nbt.4192
   PubMed Web of Science ®Google Scholar
• Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023;24(3):161–177. doi:10.1038/s41576-022-00541-1
   PubMed Web of Science ®Google Scholar
• Qi Y, Liu Y, Yu B, et al. A Lactose-Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma. Adv. Sci. 2020;7(17):2001424. doi:10.1002/advs.202001424
   Web of Science ®Google Scholar
• Nie -J-J, Liu Y, Qi Y, et al. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma. J Control Release. 2021;333:362–373. doi:10.1016/j.jconrel.2021.03.030
   PubMed Web of Science ®Google Scholar
• Gao J, Luo T, Lin N, Zhang S, Wang J. A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy. Molecular Therapy - Oncolytics. 2020;19:79–92. doi:10.1016/j.omto.2020.09.004
   PubMed Web of Science ®Google Scholar
• Zhang B-C, Luo B-Y, Zou -J-J, et al. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core–Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy. ACS Appl. Mater. Interfaces. 2020;12(51):57362–57372. doi:10.1021/acsami.0c17660
   PubMed Web of Science ®Google Scholar
• Liu Q, Fan D, Adah D, et al. CRISPR/Cas9‑mediated hypoxia inducible factor‑1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma. Oncol Rep. 2018;40(5):2547–2557. doi:10.3892/or.2018.6667
   PubMed Web of Science ®Google Scholar
• Zhang B-C, P-Y W, Zou -J-J, et al. Efficient CRISPR/Cas9 gene-chemo synergistic cancer therapy via a stimuli-responsive chitosan-based nanocomplex elicits anti-tumorigenic pathway effect. Chem Eng J. 2020;393:124688. doi:10.1016/j.cej.2020.124688
   Web of Science ®Google Scholar
• Zhuang J, Tan J, Wu C, et al. Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy. Nucleic Acids Res. 2020;48(16):8870–8882. doi:10.1093/nar/gkaa683
   PubMed Web of Science ®Google Scholar
• Yin H, Sun L, Pu Y, et al. Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma. ACS Cent. Sci. 2021;7(12):2049–2062. doi:10.1021/acscentsci.1c01143
   PubMed Web of Science ®Google Scholar
• He C, Jaffar Ali D, Qi Y, et al. Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells. J Nanobiotechnol. 2023;21(1):154. doi:10.1186/s12951-023-01902-6
   PubMed Web of Science ®Google Scholar
• He C, Jaffar Ali D, Xu H, et al. Epithelial cell -derived microvesicles: a safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib. Exp. Cell. Res. 2020;392(2):112040. doi:10.1016/j.yexcr.2020.112040
   PubMed Web of Science ®Google Scholar
• Wan T, Zhong J, Pan Q, Zhou T, Ping Y, Liu X. Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci Adv. 2022;8(37):eabp9435. doi:10.1126/sciadv.abp9435
   PubMed Web of Science ®Google Scholar
• Li C, Yang T, Weng Y, et al. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioact. Mater. 2022;9:590–601. doi:10.1016/j.bioactmat.2021.05.051
   PubMed Web of Science ®Google Scholar
• Jiang T, Sánchez‐Rivera FJ, Soto‐Feliciano YM, et al. Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Hepatology. 2021;74(1):458.
   PubMed Web of Science ®Google Scholar
• Sun Z, Xue S, Zhang M, et al. Aberrant NSUN2-mediated m5C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene. 2020;39(45):6906–6919. doi:10.1038/s41388-020-01475-w
   PubMed Web of Science ®Google Scholar
• Xiong L, Wu F, Wu Q, et al. Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nat Commun. 2019;10(1):335. doi:10.1038/s41467-018-08245-z
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang W, Ding Y, Guo X, Yuan Y, Li D. CRISPR/Cas9-mediated genome engineering of CXCR4 decreases the malignancy of hepatocellular carcinoma cells in vitro and in vivo. Oncol Rep. 2017;37(6):3565–3571. doi:10.3892/or.2017.5601
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang F, Chen Q, Wan C, Xiong J, Xu J. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway. J Exp Clin Cancer Res. 2019;38(1):467. doi:10.1186/s13046-019-1462-y
   PubMed Web of Science ®Google Scholar
• Kwan S-Y, Sheel A, Song C-Q, et al. Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes. Hepatology. 2020;71(1):275–290. doi:10.1002/hep.30807
   PubMed Web of Science ®Google Scholar
• Bao MH-R, Yang C, Tse AP-W, et al. Genome-wide CRISPR-Cas9 knockout library screening identified PTPMT1 in cardiolipin synthesis is crucial to survival in hypoxia in liver cancer. Cell Rep. 2021;34(4):108676. doi:10.1016/j.celrep.2020.108676
   PubMed Web of Science ®Google Scholar
• Wei L, Chiu DK-C, Tsang FH-C, et al. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2017;67(4):758–769. doi:10.1016/j.jhep.2017.05.015
   PubMed Web of Science ®Google Scholar
• Fu L, Wang X, Yang Y, et al. Septin11 promotes hepatocellular carcinoma cell motility by activating RhoA to regulate cytoskeleton and cell adhesion. Cell Death Dis. 2023;14(4):280. doi:10.1038/s41419-023-05726-y
   PubMed Web of Science ®Google Scholar
• Lu J, Ding Y, Zhang W, et al. SQSTM1/p62 Knockout by Using the CRISPR/Cas9 System Inhibits Migration and Invasion of Hepatocellular Carcinoma. Cells. 2023;12(9):1238.
   PubMed Web of Science ®Google Scholar
• Ardelt MA, Fröhlich T, Martini E, et al. Inhibition of Cyclin‐Dependent Kinase 5: a Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy. Hepatology. 2019;69(1):634.
   Web of Science ®Google Scholar
• Liu H, Li D, Zhou L, et al. LMNA functions as an oncogene in hepatocellular carcinoma by regulating the proliferation and migration ability. J Cell & Mol Med. 2020;24(20):12008–12019. doi:10.1111/jcmm.15829
   PubMed Web of Science ®Google Scholar
• He L, Fan X, Li Y, et al. Overexpression of zinc finger protein 384 (ZNF 384), a poor prognostic predictor, promotes cell growth by upregulating the expression of Cyclin D1 in Hepatocellular carcinoma. Cell Death Dis. 2019;10(6):444. doi:10.1038/s41419-019-1681-3
   PubMedGoogle Scholar
• Li B, Cao Y, Meng G, et al. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2019;39:239–254. doi:10.1016/j.ebiom.2018.11.063
   PubMed Web of Science ®Google Scholar
• Zhu P, Wang Y, He L, et al. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. J Clin Invest. 2015;125(10):3795–3808. doi:10.1172/JCI81979
   PubMed Web of Science ®Google Scholar
• Lu Y, Chan Y-T, Tan H-Y, et al. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2022;41(1):3. doi:10.1186/s13046-021-02208-x
   PubMed Web of Science ®Google Scholar
• Tsai C-N, S-C Y, Lee C-W, et al. SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo. Oncogene. 2020;39(24):4695–4710. doi:10.1038/s41388-020-1319-z
   PubMed Web of Science ®Google Scholar
• Luo J, Wang D, Zhang S, et al. BolA family member 2 enhances cell proliferation and predicts a poor prognosis in hepatocellular carcinoma with tumor hemorrhage. J Cancer. 2019;10(18):4293–4304. doi:10.7150/jca.31829
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shi W-Y, He W, et al. FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity. Exp. Cell. Res. 2020;387(1):111714. doi:10.1016/j.yexcr.2019.111714
   PubMed Web of Science ®Google Scholar
• Jiang J, Chen Y, Zhang L, et al. i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations. Mol Cancer. 2022;21(1):164. doi:10.1186/s12943-022-01612-x
   PubMed Web of Science ®Google Scholar
• Iwagami Y, Huang CK, Olsen MJ, et al. Aspartate β‐hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma. Hepatology. 2016;63(4).
   PubMed Web of Science ®Google Scholar
• Wang H, Guo R, Du Z, et al. Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors. Mol Ther Nucleic Acids. 2018;11:23–33. doi:10.1016/j.omtn.2018.01.002
   PubMedGoogle Scholar
• Sgro A, Cursons J, Waryah C, et al. Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma. Clin epigenetics. 2023;15(1):73. doi:10.1186/s13148-023-01482-0
   PubMed Web of Science ®Google Scholar
• Ye S, Ni Y. lncRNA SNHG9 Promotes Cell Proliferation, Migration, and Invasion in Human Hepatocellular Carcinoma Cells by Increasing GSTP1 Methylation, as Revealed by CRISPR-dCas9. Original Research. Front Mol Biosci. 2021;8. doi:10.3389/fmolb.2021.649976
   Web of Science ®Google Scholar
• Cheng F, Hansson VC, Georgolopoulos G, Mani K. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior. Glypican-1; TCGA; bladder carcinoma; hepatocellular carcinoma; glioma. Oncotarget. 2023;14(1).
   Google Scholar
• Wei L, Lee D, Law C-T, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun. 2019;10(1):4681. doi:10.1038/s41467-019-12606-7
   PubMed Web of Science ®Google Scholar
• Chen D, Zou J, Zhao Z, et al. TXNDC9 promotes hepatocellular carcinoma progression by positive regulation of MYC-mediated transcriptional network. Cell Death Dis. 2018;9(11):1110. doi:10.1038/s41419-018-1150-4
   PubMedGoogle Scholar
• Wang W, Hu B, Qin -J-J, et al. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019;6(4):419–430. doi:10.1016/j.gendis.2019.06.001
   PubMed Web of Science ®Google Scholar
• Pott LL, Hagemann S, Reis H, et al. Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC. Oncotarget. 2017;8(7).
   PubMedGoogle Scholar
• Lee HK, Lim HM, Park S-H, Nam MJ. Knockout of Hepatocyte Growth Factor by CRISPR/Cas9 System Induces Apoptosis in Hepatocellular Carcinoma Cells. Journal of Personalized Medicine. 2021;11(10):983.
   PubMed Web of Science ®Google Scholar
• He J, Zhang W, Li A, Chen F, Luo R. Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition. Biochem. Biophys. Res. Commun. 2018;500(2):177–183. doi:10.1016/j.bbrc.2018.04.017
   PubMed Web of Science ®Google Scholar
• Shangguan D, Meng L, Cao ZC, et al. Identification of Liver Cancer-Specific Aptamers Using Whole Live Cells. Anal. Chem. 2008;80(3):721–728. doi:10.1021/ac701962v
   PubMed Web of Science ®Google Scholar
• Kubes P, Jenne C. Immune Responses in the Liver. Ann Rev Immunol. 2018;36(1):247–277. doi:10.1146/annurev-immunol-051116-052415
   PubMedGoogle Scholar
• Zheng M, Tian Z. Liver-Mediated Adaptive Immune Tolerance. Front Immunol. 2019;10:2525. doi:10.3389/fimmu.2019.02525
   PubMed Web of Science ®Google Scholar
• Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic Review on CAR-T Cell Clinical Trials Up to 2022: academic Center Input. Cancers. 2023;15(4):1003.
   PubMed Web of Science ®Google Scholar
• Shi D, Shi Y, Kaseb AO, et al. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: results of Phase I Trials. Clin Cancer Res. 2020;26(15):3979–3989. doi:10.1158/1078-0432.Ccr-19-3259
   PubMed Web of Science ®Google Scholar
• Sangro B, Borad MJ, Hausner PF, et al. LBO12 - Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells. J Hepatol. 2020;73:S122. doi:10.1016/S0168-8278(20)30761-3
   Web of Science ®Google Scholar
• Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775–790. doi:10.1038/s41571-022-00689-z
   PubMed Web of Science ®Google Scholar
• van Loenen MM, de Boer R, Amir AL, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci. 2010;107(24):10972–10977. doi:10.1073/pnas.1005802107
   PubMed Web of Science ®Google Scholar
• Chan JD, Lai J, Slaney CY, Kallies A, Beavis PA, Darcy PK. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat Rev Immunol. 2021;21(12):769–784. doi:10.1038/s41577-021-00539-6
   PubMed Web of Science ®Google Scholar
• Guo X, Jiang H, Shi B, et al. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Front Pharmacol. 2018;9. doi:10.3389/fphar.2018.01118
   Web of Science ®Google Scholar
• Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737. doi:10.1038/s41598-017-00462-8
   PubMed Web of Science ®Google Scholar
• Huang K, Sun B, Luo N, Guo H, Hu J, Peng J. Programmed Death Receptor 1 (PD1) Knockout and Human Telomerase Reverse Transcriptase (hTERT) Transduction Can Enhance Persistence and Antitumor Efficacy of Cytokine-Induced Killer Cells Against Hepatocellular Carcinoma. Med Sci Monit. 2018;24:4573–4582. doi:10.12659/msm.910903
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee J-H, Lim Y-S, et al. Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology. 2015;148(7):1383–1391.e6. doi:10.1053/j.gastro.2015.02.055
   PubMed Web of Science ®Google Scholar
• Preece R, Pavesi A, Gkazi SA, et al. CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity. Mol Ther Methods Clin Dev. 2020;19:149–161. doi:10.1016/j.omtm.2020.09.002
   PubMed Web of Science ®Google Scholar
• Mo F, Duan S, Jiang X, et al. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy. Signal Transduction and Targeted Therapy. 2021;6(1):80. doi:10.1038/s41392-021-00462-1
   PubMed Web of Science ®Google Scholar
• TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. Available from: https://clinicaltrials.gov/study/NCT04417764. Accessed December 25, 2023.
   Google Scholar
• Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors. Available from: https://clinicaltrials.gov/study/NCT04842812. Accessed December 25, 2023.
   Google Scholar
• Palmer DC, Webber BR, Patel Y, et al. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med. 2022;3(10):682–704.e8. doi:10.1016/j.medj.2022.07.008
   PubMedGoogle Scholar
• A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering. Available from: https://clinicaltrials.gov/study/NCT04426669. Accessed December 25, 2023.
   Google Scholar
• Webber BR, Lonetree C-L, Kluesner MG, et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019;10(1):5222. doi:10.1038/s41467-019-13007-6
   PubMedGoogle Scholar
• Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113–117. doi:10.1038/nature21405
   PubMed Web of Science ®Google Scholar
• Anliker B. Regulatory Considerations for Clinical Trial Applications with CRISPR-Based Medicinal Products. CRISPR J. 2022;5(3):364–376. doi:10.1089/crispr.2021.0148
   PubMedGoogle Scholar
• Xu X, Liu C, Wang Y, et al. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv. Drug Delivery Rev. 2021;176:113891. doi:10.1016/j.addr.2021.113891
   PubMed Web of Science ®Google Scholar
• Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:43157. doi:10.3389/fbioe.2023.1143157
   Web of Science ®Google Scholar
• Crudele JM, Chamberlain JS. Cas9 immunity creates challenges for CRISPR gene editing therapies. Nat Commun. 2018;9(1):3497. doi:10.1038/s41467-018-05843-9
   PubMedGoogle Scholar
• Kenjo E, Hozumi H, Makita Y, et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun. 2021;12(1):7101. doi:10.1038/s41467-021-26714-w
   PubMed Web of Science ®Google Scholar
• Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation. Front Bioeng Biotechnol. 2023;11:38596. doi:10.3389/fbioe.2023.1138596
   Web of Science ®Google Scholar
• Pierce Eric A, Aleman Tomas S, Jayasundera Kanishka T, et al. Gene Editing for CEP290-Associated Retinal Degeneration. N Engl J Med. 2024. doi:10.1056/NEJMoa2309915
   PubMed Web of Science ®Google Scholar
• Brokowski C, Adli M. CRISPR Ethics: moral Considerations for Applications of a Powerful Tool. J Mol Biol. 2019;431(1):88–101. doi:10.1016/j.jmb.2018.05.044
   PubMed Web of Science ®Google Scholar
• Madigan V, Zhang F, Dahlman JE. Drug delivery systems for CRISPR-based genome editors. Nat Rev Drug Discov. 2023;22(11):875.
   PubMed Web of Science ®Google Scholar
• Leibowitz ML, Papathanasiou S, Doerfler PA, et al. Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing. Nature Genet. 2021;53(6):895–905. doi:10.1038/s41588-021-00838-7
   PubMed Web of Science ®Google Scholar
• Cullot G, Boutin J, Toutain J, et al. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nat Commun. 2019;10(1):1136. doi:10.1038/s41467-019-09006-2
   PubMedGoogle Scholar
• Turchiano G, Andrieux G, Klermund J, et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell. 2021;28(6):1136–1147.e5. doi:10.1016/j.stem.2021.02.002
   PubMed Web of Science ®Google Scholar
• Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490–495. doi:10.1038/nature16526
   PubMed Web of Science ®Google Scholar
• Akcakaya P, Bobbin ML, Guo JA, et al. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature. 2018;561(7723):416–419. doi:10.1038/s41586-018-0500-9
   PubMed Web of Science ®Google Scholar
• Fiumara M, Ferrari S, Omer-Javed A, et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nature Biotechnol. 2023:7–15.
   PubMed Web of Science ®Google Scholar
• Neugebauer ME, Hsu A, Arbab M, et al. Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nature Biotechnol. 2023;41(5):673–685. doi:10.1038/s41587-022-01533-6
   PubMed Web of Science ®Google Scholar
• Lam DK, Feliciano PR, Arif A, et al. Improved cytosine base editors generated from TadA variants. Nature Biotechnol. 2023;41(5):686–697. doi:10.1038/s41587-022-01611-9
   PubMed Web of Science ®Google Scholar
• Kim D, Kang B-C, Kim J-S. Identifying genome-wide off-target sites of CRISPR RNA–guided nucleases and deaminases with Digenome-seq. Nature Protocols. 2021;16(2):1170–1192. doi:10.1038/s41596-020-00453-6
   PubMed Web of Science ®Google Scholar
• Zou RS, Liu Y, Gaido OER, et al. Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+. Nature Methods. 2023;20(5):706–713. doi:10.1038/s41592-023-01840-z
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Cheng C, et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2017;27(1):154–157. doi:10.1038/cr.2016.142
   PubMed Web of Science ®Google Scholar
• Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin Cancer Res. 2017;23(9):2255–2266. doi:10.1158/1078-0432.Ccr-16-1300
   PubMed Web of Science ®Google Scholar
• Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78. doi:10.1186/s12943-022-01559-z
   PubMed Web of Science ®Google Scholar
• Nishida N. Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers. 2021;13(15):3666.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnol. 2018;36(9):847–856. doi:10.1038/nbt.4195
   PubMed Web of Science ®Google Scholar
• Guizhen Z, Guanchang J, Liwen L, et al. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy. Front Endocrinol. 2022;13:869. doi:10.3389/fendo.2022.918869
   Web of Science ®Google Scholar
• Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385. doi:10.1038/s41571-019-0184-6
   PubMed Web of Science ®Google Scholar
• Song X, Liu C, Wang N, et al. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Adv. Drug Delivery Rev. 2021;168:158–180. doi:10.1016/j.addr.2020.04.010
   PubMed Web of Science ®Google Scholar
• Buquicchio FA, Satpathy AT. Interrogating immune cells and cancer with CRISPR-Cas9. Trends in Immunology. 2021;42(5):432–446. doi:10.1016/j.it.2021.03.003
   PubMed Web of Science ®Google Scholar
• Bock C, Datlinger P, Chardon F, et al. High-content CRISPR screening. Nat Rev Method Primers. 2022;2(1):8. doi:10.1038/s43586-021-00093-4
   Google Scholar
• Shi H, Doench JG, Chi H. CRISPR screens for functional interrogation of immunity. Nat Rev Immunol. 2023;23(6):363–380. doi:10.1038/s41577-022-00802-4
   PubMed Web of Science ®Google Scholar
• Dong MB, Wang G, Chow RD, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019;178(5):1189–1204.e23. doi:10.1016/j.cell.2019.07.044
   PubMed Web of Science ®Google Scholar
• Gurusamy D, Henning AN, Yamamoto TN, et al. Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. Cancer Cell. 2020;37(6):818–833.e9. doi:10.1016/j.ccell.2020.05.004
   PubMed Web of Science ®Google Scholar
• Mamedov MR, Vedova S, Freimer JW, et al. CRISPR screens decode cancer cell pathways that trigger γδ T cell detection. Nature. 2023;621(7977):188–195.
   PubMed Web of Science ®Google Scholar